CD8A and neoplasm: Empirical evidence shows that ov-ici combined therapy significantly increases the number, density and functional ability of tumor infiltrating CD8+ T cells, while weakening the immunosuppressive effect of Treg and myeloid derived suppressor cells (MDSCs), so as to effectively overcome the ICI resistance mechanism (which has been proved in preclinical models and clinical studies) [17,31].